Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma

References

• Friedberg JW, Mauch PM, Rimsza LM. Non-Hodgkin lymphoma. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer: principles & practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2008. pp. 2098–2167.
   Google Scholar
• Rademaker J. Diagnostic imaging modalities for assessment of lymphoma with special emphasis on CT, MRI, and ultrasound. PET Clin 2006;1:219–230.
   Google Scholar
• Patrick T, Susan GA, Elizabeth A. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–216.
   PubMed Web of Science ®Google Scholar
• Avril N, Menzel M, Dose J, . Glucose metabolism of breast cancer assessed by 18-F-FDG-PET: histochemical and immunohistochemical analysis. J Nucl Med 2001;42:9–16.
   PubMed Web of Science ®Google Scholar
• Hasegawa BH, Iwata K, Wong KH, . Dual modality imaging of function and physiology. Acad Radiol 2002;9:1305–1321.
   PubMed Web of Science ®Google Scholar
• Beyer T, Townsend DW, Brun T, . A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369–1379.
   PubMed Web of Science ®Google Scholar
• Cremerius U, Fabry U, Neuerburg J, . Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998;19:1055–1063.
   PubMed Web of Science ®Google Scholar
• de Wit M, Bumann D, Beyer W, . Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997;8(Suppl. 1):57–60.
   PubMed Web of Science ®Google Scholar
• de Wit M, Bohuslavizki KH, Buchert R, . 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001;12:29–37.
   PubMed Web of Science ®Google Scholar
• Freudenberg LS, Antoch G, Schutt P, . FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004;31:325–329.
   PubMed Web of Science ®Google Scholar
• Guay C, Lepine M, Verreault J, . Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003;44:1225–1231.
   PubMed Web of Science ®Google Scholar
• Hueltenschmidt B, Sautter-Bihl ML, Lang O, . Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001;91:302–310.
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Warland V, Najjar F, . Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999;20:13–20.
   PubMed Web of Science ®Google Scholar
• Lang O, Bihl H, Hultenschmidt B, . Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease. Strahlenther Onkol 2001;177:138–144.
   PubMed Web of Science ®Google Scholar
• Lavely WC, Delbeke D, Greer JP, . FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 2003;57:307–315.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Timothy AR, Hain SF, . 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000;11(Suppl. 1):147–150.
   PubMed Web of Science ®Google Scholar
• Naumann R, Vaic A, Beuthien-Baumann B, . Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001;115:793–800.
   PubMed Web of Science ®Google Scholar
• Panizo C, Perez-Salazar M, Bendandi M, . Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma 2004;45:1829–1833.
   PubMed Web of Science ®Google Scholar
• Reinhardt MJ, Herkel C, Altehoefer C, . Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?Ann Oncol 2005;16:1524–1529.
   PubMed Web of Science ®Google Scholar
• Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003; 30(Suppl. 1):S89–S96.
   Web of Science ®Google Scholar
• Rigacci L, Castagnoli A, Dini C, . F-18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. Oncol Rep 2005;14:1209–1214.
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, . Can positron emission tomography with [18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?Br J Haematol 2001;115:272–278.
   PubMed Web of Science ®Google Scholar
• Stumpe KD, Urbinelli M, Steinert HC, . Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721–728.
   PubMedGoogle Scholar
• Weihrauch MR, Re D, Scheidhauer K, . Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930–2934.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Lymphoma. 2011. Available from: http://www.nccn.org/professionals/physician_gls_guidelines.asp
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Brepoels L, Stroobants S, De Wever W, . Hodgkin lymphoma: response assessment by revised International Workshop Criteria. Leuk Lymphoma 2007;48:1539–1547.
   PubMed Web of Science ®Google Scholar
• Brepoels L, Stroobants S, De Wever W, . Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma 2007; 48:1522–1530.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L, . Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746–3752.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Qian W, Somer EJ, . Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:1824–1833.
   PubMed Web of Science ®Google Scholar
• Schöder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin North Am 2008;46:225–241.
   PubMed Web of Science ®Google Scholar
• Terasawa T, Nihashi T, Hotta T, . 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: a systematic review. J Nucl Med 2008;49:13–21.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Timothy AR, O’Doherty MJ, . 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 2000; 39:543–553.
   PubMed Web of Science ®Google Scholar
• Hicks RJ, Kalff V, MacManus MP, . The utility of 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001;42:1605–1613.
   PubMed Web of Science ®Google Scholar
• Lin C, Itti E, Haioun C, . Early 18 F FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007;48: 1626–1632.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115–123.
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, . [(18)F]FDG-PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?Eur J Nucl Med Mol Imaging 2003;30:682–688.
   PubMed Web of Science ®Google Scholar
• Le Roux PY, Gastinne T, Le Gouill S, . Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging 2011;38:1064–1071.
   PubMed Web of Science ®Google Scholar
• Weiler Sagie M, Bushelev O, Epelbaum R, . (18)F FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010;51:25–30.
   PubMed Web of Science ®Google Scholar
• Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50(Suppl. 1):11S–20S.
   Google Scholar